(XRAY) Dentsply Sirona - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US24906P1093
XRAY: Dental, Equipment, Implants, Solutions, Technologies, Products
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) stands as a leader in dental and medical technologies, operating across four core segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. This structure allows the company to cater to a broad spectrum of dental and medical needs, from diagnostics and treatment to restorative and orthodontic solutions.
The companys product portfolio is extensive, encompassing imaging equipment, CAD/CAM technologies, and a cloud-based platform called DS Core. Their offerings include intraoral scanners, 3D printers, and mills, which are integral to modern dental restorations. Additionally, they provide endodontic tools, restorative materials like ceramics and veneers, and preventative products such as curing lights and ultrasonic scalers. Their orthodontic solutions include SureSmile and Byte aligners, complemented by VPro/HyperByte vibration technology for enhanced treatment outcomes.
Financially, DENTSPLY SIRONA boasts a market capitalization of approximately $4 billion, with a forward P/E ratio of 10.07 and a P/S ratio of 1.04, indicating a moderate valuation relative to its revenue. These metrics suggest a company that is well-established yet still poised for growth, particularly in the evolving dental technology landscape.
With a rich history dating back to 1877, DENTSPLY SIRONA has established itself as a trusted name, serving dental professionals and healthcare providers globally. Their commitment to innovation and comprehensive solutions underscores their position as a key player in the healthcare supplies industry.
Additional Sources for XRAY Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
XRAY Stock Overview
| Market Cap in USD | 2,985m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Health Care Supplies |
| IPO / Inception | 1987-08-12 |
XRAY Stock Ratings
| Growth 5y | -73.3% |
| Fundamental | -36.3% |
| Dividend | 67.7% |
| Rel. Strength Industry | -52 |
| Analysts | 3.63/5 |
| Fair Price Momentum | 12.29 USD |
| Fair Price DCF | 32.63 USD |
XRAY Dividends
| Dividend Yield 12m | 3.21% |
| Yield on Cost 5y | 1.95% |
| Annual Growth 5y | 9.86% |
| Payout Consistency | 94.2% |
XRAY Growth Ratios
| Growth Correlation 3m | -48.2% |
| Growth Correlation 12m | -92.3% |
| Growth Correlation 5y | -78.7% |
| CAGR 5y | -13.80% |
| CAGR/Max DD 5y | -0.18 |
| Sharpe Ratio 12m | -0.77 |
| Alpha | -55.16 |
| Beta | -0.10 |
| Volatility | 34.58% |
| Current Volume | 3362.9k |
| Average Volume 20d | 2886k |
As of March 15, 2025, the stock is trading at USD 15.56 with a total of 3,362,863 shares traded.
Over the past week, the price has changed by -4.66%, over one month by -15.07%, over three months by -19.90% and over the past year by -51.59%.
Probably not. Based on ValueRay Fundamental Analyses, Dentsply Sirona (NASDAQ:XRAY) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -36.30 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of XRAY as of March 2025 is 12.29. This means that XRAY is currently overvalued and has a potential downside of -21.02%.
Dentsply Sirona has received a consensus analysts rating of 3.63. Therefor, it is recommend to hold XRAY.
- Strong Buy: 3
- Buy: 4
- Hold: 9
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, XRAY Dentsply Sirona will be worth about 13.3 in March 2026. The stock is currently trading at 15.56. This means that the stock has a potential downside of -14.72%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 20 | 28.5% |
| Analysts Target Price | 23 | 47.6% |
| ValueRay Target Price | 13.3 | -14.7% |